Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 5/20 | 0.37 |
| ▸ | UBE2M | P61081 | 2/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 3/20 | 0.35 |
| ▸ | PPARA | Q07869 | 3/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2262702 | 0.86 | CHRM5 (0.35) | UBE2MDCUN1D1ALDH1A1CYP3A4MEN1 | |
| SCHEMBL1901365 | 0.77 | LOXL2 (0.40) | PARP1CASRNR3C1ALDH1A1SLC7A5 | |
| SCHEMBL1902763 | 0.72 | DUSP3 (0.39) | ALDH1A1 | |
| SCHEMBL16279837 | 0.69 | PTGES (0.38) | PPARGNR3C1ALDH1A1MEN1KMT2A | |
| SCHEMBL5669028 | 0.69 | PTGES (0.39) | DCUN1D1NR3C1MEN1KMT2A | |
| SCHEMBL5669271 | 0.68 | CYP2D6 (0.46) | ALDH1A1CYP3A4MAPK1MEN1KMT2A | |
| SCHEMBL1899307 | 0.67 | DUSP3 (0.37) | PPARGPPARAALDH1A1MAPK1MEN1 | |
| SCHEMBL1902779 | 0.67 | HTT (0.39) | PPARGPPARAALDH1A1MAPK1 | |
| SCHEMBL2265549 | 0.66 | CYP3A4 (0.33) | UBE2MDCUN1D1CYP3A4MAPK1 | |
| SCHEMBL5669773 | 0.65 | HCAR3 (0.40) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | claimed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | claimed |
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | JAPAN TOBACCO INC. (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | JAPAN TOBACCO INC. (JP) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | PARP1 2137/4885CASR 4404/4885UBE2M 2671/4885 |
| US-20110189210-A1 | METHOD OF INHIBITING REMNANT LIPOPROTEIN PRODUCTION | CETP, PCSK9, LIPA | PARP1 2137/4885CASR 4404/4885UBE2M 2671/4885 |
| US-20060270705-A1 | Method for inhibiting lipid absorption and lipid absorption inhibitor | CETP, SI, LIPC | PARP1 3584/4885CASR 3524/4885UBE2M 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.